Cue Biopharma, Inc. Accrued Liabilities, Current
Cue Biopharma, Inc. (CUE) had Accrued Liabilities, Current of $14.88 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Accrued Liabilities, Current $14.88M.
- 2026-03-31: Accrued Liabilities, Current $1.50M.
- 2025-12-31: Accrued Liabilities, Current $1.61M.
- 2025-09-30: Accrued Liabilities, Current $1.87M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $14.88M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $1.61M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $1.87M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $1.52M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $4.23M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $2.91M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $3.20M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $4.56M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $5.21M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $4.14M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $5.13M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $4.08M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $2.84M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $3.55M 10-K · filed 2024-03-28 | $3.55M 10-K · filed 2023-03-21 |
| 2022-09-30 | $3.88M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $3.56M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $3.41M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $4.62M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $3.99M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $2.00M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $1.98M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $2.79M 10-K · filed 2022-03-16 | |
| 2020-09-30 | $2.58M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $4.06M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $1.14M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $2.23M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $1.55M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $2.58M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $2.15M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $1.79M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $2.27M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $1.12M 10-Q · filed 2018-08-13 | |
| 2017-12-31 | $1.15M 10-K · filed 2019-03-14 | $1.15M 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |